Sammanfattning
Post-myocardial infarction beta-blocker therapy is based on studies from the early 1980s. Since then, the diagnostics for
myocardial infarction have become more sensitive, revascularisation has improved survival and there are now improved
secondary prophylaxis drugs. We therefore believe it is time for new research, and that the indication for routine beta-blocker
therapy following myocardial infarction should be reviewed.